Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: A nested case-control study based on Italian healthcare utilization databases

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 7, 2015, Pages 771-778

  Bosetti, Cristina ^a   Franchi, Matteo ^b   Nicotra, Federica ^b   Asciutto, Rosario ^c   Merlino, Luca ^d   La Vecchia, Carlo ^e   Corrao, Giovanni ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d delle Strategie e Piani del Sistema Sanitario   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Antidiabetics; Diabetes; Hepatocellular carcinoma; Insulin; Metformin; Pharmacoepidemiology

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; INCRETIN; INSULIN; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; REPAGLINIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CANCER RISK; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL DISCHARGE; HUMAN; INSULIN SENSITIVITY; INSULIN TREATMENT; ITALY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; CASE CONTROL STUDY; CHEMICALLY INDUCED; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG DATABASE; DRUG UTILIZATION; LIVER NEOPLASMS; ODDS RATIO; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; DATABASES, PHARMACEUTICAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ITALY; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT;

EID: 84933670325     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3801     Document Type: Article

References (49)

1. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380.
2. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-1008.
3. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012; 130: 1639-1648.
4. Bosetti C, Rosato V, Polesel J, et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Cancer 2012; 64: 643-651.
5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468.
6. Dellon ES, Shaheen NJ. Diabetes and hepatocellular carcinoma: associations, biologic plausibility, and clinical implications. Gastroenterology 2005; 129: 1132-1134.
7. Beasley RP. Diabetes and hepatocellular carcinoma. Hepatology 2006; 44: 1408-1410.
8. Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-2511.
9. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-1946.
10. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758.
11. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 2011; 11: 20.
12. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46-52.
13. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012; 35: 119-124.
14. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: E1170-1175.
15. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615.
16. Hagberg KW, McGlynn KA, Sahasrabuddhe VV, Jick S. Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer 2014; 111: 1710-1717.
17. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Arnold Chan K. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462-1472.
18. Chiu CC, Huang CC, Chen YC, et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med 2013; 52: 939-946.
19. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013; 18: 148-156.
20. Schlesinger S, Aleksandrova K, Pischon T, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 2013; 24: 2449-2455.
21. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-891; quiz 892.
22. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndrome: Clin Res Rev 2008; 2: 47-57.
23. Asciutto R, Lugo A, Gallus S, Roncaglioni M, La Vecchia C, Bosetti C. Prevalence and determinants of diabetes mellitus in a representative sample of Italian adults. Epidemiol Biostatistics and Public Health 2014; 11: e9980.9981-e9980.9988.
24. EPICENTRO. Rapporto nazionale Passi 2011: diabete. Available at: http://www.epicentro.iss.it/passi/diabete2010.asp Last accessed March 2015.
25. Corrao G, Cesana G, Merlino L. Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy. BioMed Stat Clin Epidemiol 2008; 2: 111-125.
26. WHO Collaborating Centre for Drug Statistics Methodology, eds. ATC classification index including defined doses for plain substances. Available at: http://www.whocc.no/atc_ddd_index/ [15 September 2014].
27. Breslow NE, Day NE (eds). Statistical methods in cancer research. Vol. I. The Analysis of Case-control Studies. IARC Sci Publ No. 32. IARC: Lyon, France, 1980.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
29. Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 2011; 1243: 54-68.
30. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9: 33.
31. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-260.
32. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
33. Steinberg GR, Macaulay SL, Febbraio MA, Kemp BE. AMP-activated protein kinase - the fat controller of the energy railroad. Can J Physiol Pharmacol 2006; 84: 655-665.
34. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-341.
35. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
36. La Vecchia C. Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism 2011; 60: 1357-1358.
37. Pasello G, Urso L, Conte P, Favaretto A. Effects of sulfonylureas on tumor growth: a review of the literature. Oncologist 2013; 18: 1118-1125.
38. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
39. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-743.
40. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342: 1907-1909.
41. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with type 2 diabetes: a longitudinal study. BMC Public Health 2005; 5: 36.
42. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-2673.
43. Corrao G, Zambon A, Conti V, et al. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 2008; 19: 150-155.
44. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365.
45. Hense HW, Kajuter H, Wellmann J, Batzler WU. Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr 2011; 3: 15.
46. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 6/10/2014
47. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28: 753-770.
48. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
49. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 2012; 23: 991-1008.